A more recent Chinese study pointed to benefits with single-agent ATO in the hard-to-treat elderly, with 88% of patients, aged 60 years or older, achieving a complete remission. The 10-year cumulative incidence of relapse was 10.3% after a median follow-up of 99 months, during which time no patient died of ATO-related toxicities (Cancer 2013;119:115-25).
Dr. Lo-Coco reported serving on the board of directors or advisory committees for Boehringer Ingelheim and as a speaker for Cephalon, the maker of Trisenox (arsenic trioxide). His coauthors reported relationships with several pharmaceutical firms.